Herpes simplex 1 (HSV-1) infection is often underestimated, despite the global seroprevalence of the virus, present in about 3709 million people. It is estimated that both HSV-1 and Herpes simplex type 2 (HSV-2) are present in the oral cavity even in the absence of symptoms and clinical lesions. This infectious disease can result in severe and highly relapsing forms, especially in immunosuppressed patients, and it can cause serious complications. Our aim was to consider three issues:
(i) the rate of the asymptomatic diffusion of both HSV-1 and HVS-2, from the oral cavity of immunosuppressed and immunocompetent patients;
(ii) the re-exacerbation following dental treatments;
(iii) the professional risk for the members of the medical team, in order to apply the appropriate safety procedures.
Materials and Methods
Three systematic analyzes/inclusion criteria were performed by using medical and health databases: (i) only in vivo human studies and clinical investigations based only on samples taken from oral sites with direct positive laboratory diagnosis; (ii) the second one included the papers in which is reported recurrent herpetic infection after dental treatment; (iii) the third one included all cases of herpetic infection, got by the medical teams in their work structures, in any tissue site. Various combinations of keywords were used: Herpes simplex virus, HSV-1, HSV-2, saliva, dental extraction, procedure, treatment, transmission, dentist, occupational risk. Out of a total of 1282 studies, 73 fitted the inclusion criteria.
Results
Results point out that the main HSV spread mode is asymptomatic, regardless of the immune status of individuals. According to our literature analysis, HSV-1 is the most excreted virus in immunocompetent subjects, while HSV-2 is also detected in subjects with altered immune status, although it occurs less frequently and often in association with the recurrent genital lesion. The amount of total and type I HSV DNA is statistically more detectable in HIV positive and oncological patients than in immunocompetent patients (p<0,01) but not in transplant patients (p>0,01). HSV-2 is more detectable in HIV positive patients than healthy ones (p<0,01) but not in cancer and transplant patients (p>0,01).
Conclusions
As for the exacerbation of HVS-1 after dental treatments, studies in literature are discordant: some show a significant correlation, others opposite outcomes. Finally, as for the professional risk, the dental medical team appears to be more exposed to the infection than common population. Indeed, several cases of herpetic infection have been reported following the treatment of patients with active lesions; most of them are represented by herpetic whitlow, which incidence has decreased, i.e. as ocular keratitis, thanks to the use of individual protection devices, DPI.
Clinical implications
The morbidity related with HSV infection is often associated with the increasing number of immunocompromised patients observed in these last decades has significant implications in daily outpatient treatment. In addition, the presence of severe and refractory lesions in apparently healthy individuals must always be carefully evaluated by dentists. At the present, there are no well-standardized protocols regarding the treatment of patients with oral herpetic infection. In this context an exhaustive procedure is strictly needed in supporting a good clinical governance in the oral medical practice.
Oral pathology 02 June 2026
This peer-reviewed oral pathology article summarizes clinical evidence from Oral oncology (2026). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...
Oral pathology 27 May 2026
This peer-reviewed oral pathology article summarizes clinical evidence from BMC oral health (2024). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...
Oral pathology 26 May 2026
This peer-reviewed oral pathology article summarizes clinical evidence from Oral oncology (2026). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...
Oral pathology 18 May 2026
This peer-reviewed oral pathology article summarizes clinical evidence from Oral oncology (2026). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...
Oral pathology 13 May 2026
This peer-reviewed oral pathology article summarizes clinical evidence from BMC oral health (2024). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...
New initiative invites dentists to experience DEXIS’ most advanced AI yet, built on scale, speed, and clinical trust.
News 05 June 2026
(Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/C
News 05 June 2026
(Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected Will
As the University of Colorado School of Dental Medicine celebrates the graduating DDS Class of 2025, we are proud to recognize the students and faculty members whose exceptional de
Oral surgery 05 June 2026
This peer-reviewed oral surgery article summarizes clinical evidence from International journal of oral and maxillofacial surgery (2026). It focuses on findings that may help dental professionals...